1. |
Finelt M, Hoffmann MK. A human monocyte function test: release of B cell differentiation factor (BDF). Clin Immun Immunopath,1979;12:281.
|
2. |
Pollack S, Micall A, Kinne DW, et al. Endotoxin-induced in vitro release of interleukin- by canxer patients’ monocytes: relation tp stage of disease. Int J Cancer,1983;32:733.
|
3. |
Moldawer LL, Drott C, Lundholm K. Monicytic production and plasma bioactivityes of imterleukin 1 and tumour necrosis factor in human cancer. Euro J Clin Inves, 1988;18:486.
|
4. |
Haga Y, Sakamoto K, Egami H, et al. Changes in prduction of intereleukin-1 and inter leukin-2 associated with obstrective jaundice and biliary drainage in patients with gastrointestinal cancer .Surgery, 1989;106:842.
|
5. |
Ikemoto S, Kishimoto T, Iimoti H, et al. Defective interleukin-1 production of monocytes in patients with bladder cancer . Brit J Uro;ogy, 1990;65:181.
|
6. |
Sone S, Utsugi T, Tanaon P, et al. Tumor cytotoxicity and interleukin-1 production of blood monocytes of lung cancer patients. Cancer Immunol Immunother, 1990;30:257.
|
7. |
North RJ, Th concept of the activated macrophage. J Immunol ,1978;121:806.
|
8. |
Fidler IJ, Barnes Z, Pogler We, et al. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res, 1982;42:496.
|
9. |
Onozaki K, Matsuchima K, Kleinerman ES, et al. Role of interleukin-1 in promoting human monocyte-mediated tumor cytotoxicity. J Immunol, 1985;135:341.
|
10. |
Mannel DN, Moore RN, Mergenhagen SE. Macrophages as source of tumo icidal activity (Tumor-nectotizing-Fac-tor).Infect Immun,1980;30:523.
|
11. |
Varesio L, Blasi E, Thurman GB, et al. Potent activation of mouse macrophage by recmbinant interferon-ν.Cancer Res, 1984;44:4465.
|
12. |
Nakamura S, Nakata K, Kachimoto S, et al. Antitumor effect of recombinant human interleukin 1 alpha against murine sysgeneic tumors. JPN J Cancer es ,1986;77:767.
|
13. |
Izumi Y, Tsuchida T, Okuno K, et al. Enhanced induction of tumorspecific Lyt 1+2-T cell mediated protective immunity by in vivo administration of interleukin 1. JPN J Cancer Res, 1985;76:863.
|
14. |
Lomedico PT, Gubler U, Hellman CP, et al. Cloning and expression of murine interleukin 1 cDNA in escherichia coli. nature, 1984;321:458.
|
15. |
Furutani Y, Notake M, Yamayoshi M, et al. Cloning and characterization of the cDNAa for human rabbit interleukin-1 precursor .Nucleic Acids Res, 1985;13:5869.
|
16. |
March CJ, Mosley B, Larsen A, et al. Clning, sequence and expression of two distinct human inerleikin-1 complementary DNAs, Nature, 1985;515:641.
|
17. |
Onoxaki K, Matsushima K, Aggarwal BB, et al. Human interleukin 1 is a cytocisal factor for several tumor cell lines. J Immunol, 1985;135:3962.
|
18. |
Onozaki K, Takuya T, Hashimoto T, et al. Growth inhibition differentiation by interleukin 1. Cancer Res, 1987;47:2397.
|
19. |
Tsai SC, Gaffnney EV, Modulation of cell proliferation by human recombinant interleukin-1 and immune in terferon. J Natl Cancer Invest, 1987;79:77.
|
20. |
Mornaga Y, Suzuki H, Takatsuki F, et al.Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis on tumor cell lines. J Immunol, 1989;143:3583.
|
21. |
Paciotti GF, Tamarkin L. Interleukin-1 directly regulaes hormone-dependent human breast cancer cell proliferation in vitro. Mol Endocrinol, 1988;2:459.
|
22. |
Belardelli F, Ciolli V, Testa U, et al. Anti-tumor effect of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors. Int J Cancer, 1989;44:1108.
|
23. |
Yamashita U, Shirakawa F. Restoration of impaired T T cell function in tumor-bearing mice by the administration of interleukin 1. JPN J Cancer Res, 1987;78:270.
|
24. |
Blumenthal RD, Sharkey RM, Snyder DJ, e tal. Reduction of radioantibody-induced myelotoxicity in hamsteers by recombinant interleukin 1. Cancer Res, 1988;48:5403.
|
25. |
Sharkey RM, Blumanthal RD, hansen HJ, et al. Biological consideration for radioimmunotherapy. Cancer Res, 1990;50(3 suppl ):964s.
|
26. |
Blumenthal RD, Sharkey RM, Quinn LM, et al. Use of hematopoietic growth factors to control myelosuppression caused by radioimmunotherapy. Cancer Res, 1990;50(3 suppl):1003.
|
27. |
Mccune CS, Marquis DM. Interleukin 1 as a adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res, 1990;50;1212.
|
28. |
Forni G, Giovarelli M, Bosco MC, et al. Lymphkine-anticated tumor inhibition: conbinatory activity of a synthetic nonapeptide from interleukin-1, interleukin-2, interleukin-4 and interon-ν injected around tumor-draining lymph nodes. Int J Cancer Suppl, 1989;4:62.
|
29. |
Constantinidis I, Braunschweiger PG, Wehrle JP, et al. 31 P-neclear magnetic resonance studies of the effec of recombinant human interleukin 1 α on the bioenergetics of RIF-1 tumors . Cancer Res, 1989;49:6379.
|
30. |
Nakata K, Kachimoto S, Yoshida H, et al, Augmented antitumor effect of recombinanat human interleukin-1 by indomethacin. Cancer Res, 1988;48:584.
|
31. |
李康生,田志刚,崔正言.白细胞介素-1的抗肿瘤效应.国外医学免疫学分册,1990;13:57.
|